Somehow, I don't really think you're really laughing at all. Quite the contrary. You are desperately trying to manage impressions of anyone stupid, like you, who reads this MB. And quite literally, on a 24/7/365 basis. I check in now and then and you and your ridiculous aliases are an ever-present plague upon this board, teri.
You're so boring and predictable. You have no life outside of this stupid board. What you think you can accomplish here beyond annoying a few people is beyond me. I frankly don't give a dame how much time you waste here doing absolutely NOTHING. Keep up your sickness. I have you on ignore and will report your unread bilge as long as you keep throwing it against the wall .
So stop it and turn your life around. Take up a hobby, like painting by numbers. It can be highly rewarding for folks adrift like you. I don't think surfing is an option at your age.
Insmed Limited; Treatment of Mycobacterium avium Complex (MAC) lung disease in
adult patients who have persistent positive sputum cultures despite the use of medically
appropriate first-line therapy
Scope: Oral explanation
Action: Oral explanation to be held on 24 May 2016 at 14.00.
List of Outstanding Issues adopted on 25.02.2016. List of Questions adopted on
After some delay , I was able to hear the tail end of the presentation and questions. He said enrollment in CONVERT was going very well and surprisingly so in Asia. Nothing else really new from answers to other questions. I almost pulled the buy trigger this morning, but I see now we have headed up with XBI, (for now).
As a fellow (part-time) musician, I know you have a rich life apart from this board. I didn't bet the farm on this stock, though my holdings are substantial and luckily I bought when prices were much lower and I am still way green. I know that nothing is guaranteed,and that's exactly what you realize when you cast a fishing line into waters that even you think you know fairly well. I like sitting in a boat waiting for the bite. You could be listening to Elgar or Vaughan-Williams in the interim. So enjoy all that is at your disposal and enjoy not engaging a very sick person who we should pity and hope for their eventual recovery and redemption.
Some interesting comments from the 10k:
In addition to our patents and trade secrets, we have filed applications to register certain trademarks in the US and/or abroad, including INSMED, ARIKAYCE, and IPLEX.
In May 2012, we entered into an agreement with Premacure pursuant to which we granted to Premacure an exclusive, worldwide license to develop manufacture and commercialize IGF-1, with its natural binding protein, IGFBP-3... get that...MANUFACTURE.
Funny that they would call the study "pre-clincal" as LAI has been in the clinic for years. Threw me off. I thought they were starting to work on another disease.
From the press release, Data accepted for presentation at ATS 2016: (iii) a preclinical study of ARIKAYCE.
Any guesses as as to what indication they are targeting?
I live on a long and winding gravel road. One of my neighbors had this dog that had a sport of chasing every vehicle that came along. I found a way of breaking him of that habit. I just shifted into low gear and kicked up a cloud of dust which enveloped him every time he chased me. He soon tired of breathing in all that dry dust and gave it up, just like TIP users eventually will, it it irritates them too.
Arikayce is likewise differentiated from TOBI, carried in lung-friendly surfactant actually made of the same stuff native to human lungs. Arikayce for Ps in CF will be revisited sooner rather than later.
How about the study using iPlex in which the authors claim the therapy "represent(s) a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases." The title is "Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A," so a google search should pull it up. I wonder if there is any follow-up on this work published in the journal, Human Molecular Genetics in June 2013. And don't forget, the company itself listed ALS as one of the orphan diseases it might address in the future and this would undoubtedly revolve around iPlex, which is Nature's own regulator of cell growth and regeneration. Genentech didn't fight for the rights to this compound for nothing and we own it in 2017.